1636 LETHALITY OF PROSTATE CANCER IN A PRIMARY RELATIVE DOES NOT APPEAR TO INCREASE THE RISK OF AGGRESSIVE MALIGNANCY

Abstract

You have accessJournal of UrologyProstate Cancer: Localized VIII1 Apr 20121636 LETHALITY OF PROSTATE CANCER IN A PRIMARY RELATIVE DOES NOT APPEAR TO INCREASE THE RISK OF AGGRESSIVE MALIGNANCY Seth A. Cohen, Kerrin L. Palazzi, Samuel K. Park, J. Kellogg Parsons, and Christopher J. Kane Seth A. CohenSeth A. Cohen San Diego, CA More articles by this author , Kerrin L. PalazziKerrin L. Palazzi San Diego, CA More articles by this author , Samuel K. ParkSamuel K. Park San Diego, CA More articles by this author , J. Kellogg ParsonsJ. Kellogg Parsons San Diego, CA More articles by this author , and Christopher J. KaneChristopher J. Kane San Diego, CA More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2012.02.1453AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail INTRODUCTION AND OBJECTIVES The risk of being diagnosed with prostate cancer is higher in men who have a first-degree relative, brother or father, with prostate cancer. It is not clear if the lethality of the family history (i.e., whether the primary relative died of prostate cancer) is related to the aggressiveness of prostate cancer in the family member himself. This investigation sought to determine if having a primary relative die of prostate cancer is associated with more aggressive prostate cancer clinically or pathologically. METHODS We retrospectively analyzed prospectively collected data from an IRB approved comprehensive urologic oncology database, identifying men with no family history of prostate cancer (NFH), a primary relative with prostate cancer who had survived the disease (FH), and those with a primary relative who had died of prostate cancer (FHD). Demographic, clinical, and pathologic outcomes were compared using Chi2 test, Fisher’s exact test, independent T test, ANOVA, Kruskal-Wallis test, and Mann-Whitney U test. RESULTS Between 2008 and 2011, 471 men who underwent radical prostatectomy at our institution had complete database consents and complete family history information: 355 in the NFH cohort, 97 in the FH cohort, and 19 in the FHD cohort. The men with a family history (FH+FHD) of prostate cancer were diagnosed slightly younger than the men without a family history (NFH): 62±6.7 (NFH), 60±7.4 (FH), and 61±7.6 (FHD) (p=0.008). The groups were similar in all demographics (BMI, rates of diabetes, hypertension, hyperlipidemia, coronary artery disease, and 5 alpha-reductase use) and clinical D’Amico Risk Group stratification. On pathologic analysis, rates of Gleason score >8 were similar within each group: 18.9% (NFH), 18.8% (FH), and 15.8% (FHD) (p=0.908). Pathologic T stage was similar in each group as well (p=0.072); T2s were found in 76.1% of NFH, 85.6% of FH, and 94.7% of FHD. T3s were found in 22.8% of NFH, 12.3% of FH, and 5.3% of FHD; T4s were found in 1.1% of NFH, 2.1% of FH, and 0% of FHD. Biochemical recurrence rates were similar within each group: 9.3% (NFH), 5.2% (FH), and 5.3% (FHD) (p=0.376). CONCLUSIONS Patients with primary relatives who have died of prostate cancer do not appear to be at increased risk for high-risk prostate cancer or biochemical recurrence after radical prostatectomy. © 2012 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 187Issue 4SApril 2012Page: e661 Advertisement Copyright & Permissions© 2012 by American Urological Association Education and Research, Inc.MetricsAuthor Information Seth A. Cohen San Diego, CA More articles by this author Kerrin L. Palazzi San Diego, CA More articles by this author Samuel K. Park San Diego, CA More articles by this author J. Kellogg Parsons San Diego, CA More articles by this author Christopher J. Kane San Diego, CA More articles by this author Expand All Advertisement Advertisement PDF downloadLoading ...